Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Daiichi Sankyo Files sNDA for Diabetes | Contract Pharma

What are you searching for?

Sign in

Daiichi Sankyo Files sNDA for Diabetes

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Daiichi Sankyo, Inc. has filed an sNDA with the FDA for WelChol to improve glycemic control in patients with type 2 diabetes mellitus. If approved, WelChol would be the first LDL cholesterol-lowering drug that also improves glycemic control.

WelChol has been shown to lower A1C in patients with type 2 diabetes mellitus. WelChol, when added to insulin, demonstrated a mean A1C reduction of 0.5% compared to placebo. In an additional WelChol study, the Glucose Lowering Effect Of WelChol Study (GLOWS), WelChol added to an oral antidiabetic therapy resulted in mean A1C reductions of 0.5% compared to placebo and 1% in patients with A1C = 8% compared to placebo.

The ADA estimates that 20.8 million people in the U.S. have diabetes, of which more than 90% have type 2 diabetes. The ADA recommends that patients with type 2 diabetes target an A1C level of less than 7%. Additionally, the National Cholesterol Education Program (NCEP) recommends that patients with type 2 diabetes keep their cholesterol levels in check and target an LDL-C goal of less than 100 mg/dL.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters